RATIO-TERAZOSIN - TAB 2MG TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

TERAZOSIN HYDROCHLORIDE

Mevcut itibaren:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATC kodu:

G04CA03

INN (International Adı):

TERAZOSIN

Doz:

2MG

Farmasötik formu:

TABLET

Kompozisyon:

TERAZOSIN HYDROCHLORIDE 2MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

ALPHA-ADRENERGIC BLOCKING AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0121210002; AHFS:

Yetkilendirme durumu:

CANCELLED POST MARKET

Yetkilendirme tarihi:

2014-09-19

Ürün özellikleri

_ _
RATIO-TERAZOSIN_ Product Monograph _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR RATIO-TERAZOSIN
terazosin hydrochloride
1 mg, 2 mg, 5 mg and 10 mg tablets
Antihypertensive Agent
Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
ratiopharm inc.
17 800 Lapointe
Mirabel, Quebec
Canada J7J 1P3
Date of Preparation:
May 2, 2002
Date of Revision:
March 3, 2011
Submission Control No: 144582
_ _
RATIO-TERAZOSIN_ Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................9
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND
ADMINISTRATION..............................................................................15
OVERDOSAGE
................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND
STABILITY..........................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
...............................................................................21
PHARMACEUTICAL
INFORMATION..........................................................................21
CLINICAL
TRIALS..............................................